Pri­or­i­ty re­view vouch­er up­dates: Who's won PRVs, who's bought them, and how much they're sell­ing for

Ar­ti­cle up­dat­ed 4/10/24 to note that Ital­far­ma­co won a rare pe­di­atric PRV for the ap­proval of Du­vyzat (givi­no­s­tat) for the treat­ment of Duchenne Mus­cu­lar Dy­s­tro­phy in chil­dren six years of age and old­er. Or­chard Ther­a­peu­tics al­so re­cent­ly won a PRV for the ap­proval of its gene ther­a­py Len­meldy (ati­darsagene au­totem­cel). 

The FDA can award bio­phar­ma com­pa­nies with pri­or­i­ty re­view vouch­ers (PRVs) fol­low­ing new ap­provals of treat­ments for ne­glect­ed trop­i­cal dis­eases, rare pe­di­atric dis­eases and med­ical coun­ter­mea­sures. The sys­tem by which PRVs are sold, typ­i­cal­ly for around $100 mil­lion each, con­tin­ues to thrive, more than a decade af­ter it was cre­at­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER